Stock Research for TTPH

TTPH
Current Price

$2.1200


Latest Update: 2018-02-16 16:00:00

High
$ 2.1200
Low
$ 2.1100
Close
$ 2.1200
Volume
49919
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

TTPH Stock Chart & Research Data

The TTPH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TTPH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TTPH Due diligence Resources & Stock Charts

The TTPH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TTPH Detailed Price Forecast - CNN Money CNN View TTPH Detailed Summary - Google Finance
Yahoo View TTPH Detailed Summary - Yahoo! Finance Zacks View TTPH Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View TTPH Trends & Analysis - Trade-Ideas Barrons View TTPH Major Holders - Barrons
NASDAQ View TTPH Call Transcripts - NASDAQ Seeking View TTPH Breaking News & Analysis - Seeking Alpha
Spotlight View TTPH Annual Report - CompanySpotlight.com OTC Report View TTPH OTC Short Report - OTCShortReport.com
TradeKing View TTPH Fundamentals - TradeKing Charts View TTPH SEC Filings - Bar Chart
WSJ View Historical Prices for TTPH - The WSJ Morningstar View Performance/Total Return for TTPH - Morningstar
MarketWatch View the Analyst Estimates for TTPH - MarketWatch CNBC View the Earnings History for TTPH - CNBC
StockMarketWatch View the TTPH Earnings - StockMarketWatch MacroAxis View TTPH Buy or Sell Recommendations - MacroAxis
Bullish View the TTPH Bullish Patterns - American Bulls Short Pains View TTPH Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View TTPH Stock Mentions - StockTwits PennyStocks View TTPH Stock Mentions - PennyStockTweets
Twitter View TTPH Stock Mentions - Twitter Invest Hub View TTPH Investment Forum News - Investor Hub
Yahoo View TTPH Stock Mentions - Yahoo! Message Board Seeking Alpha View TTPH Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for TTPH - SECform4.com Insider Cow View Insider Transactions for TTPH - Insider Cow
CNBC View TTPH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TTPH - OTC Markets
Yahoo View Insider Transactions for TTPH - Yahoo! Finance NASDAQ View Institutional Holdings for TTPH - NASDAQ


Stock Charts

FinViz View TTPH Stock Insight & Charts - FinViz.com StockCharts View TTPH Investment Charts - StockCharts.com
BarChart View TTPH Stock Overview & Charts - BarChart Trading View View TTPH User Generated Charts - Trading View


Latest Financial News for TTPH

Here's Why Tetraphase Pharmaceuticals Crashed 60.4% Today
Posted on Wednesday February 14, 2018

A key clinical trial failure sent investors fleeing for the exits.


INVESTOR ALERT: Investigation of Tetraphase Pharmaceuticals Announced by Holzer & Holzer
Posted on Wednesday February 14, 2018

Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc. complied with the federal securities laws. On February 13, 2018, Tetraphase announced that its IGNITE3 clinical trial did not achieve its co-primary endpoints of responder rate at the end of treatment and test-of-cure visit.


Here’s What’s Moving Tetraphase
Posted on Wednesday February 14, 2018

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) didn’t have a great start to the week this week. The company just put out data from a phase 3 clinical trial of one of its lead development assets, a drug called intravenous (IV) eravacycline, and the data has failed to hit the mark on a number of endpoints. In response, […] The post Here’s What’s Moving Tetraphase appeared first on Market Exclusive.


Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)
Posted on Tuesday February 13, 2018

̶ Eravacycline Did Not Achieve Co-Primary Endpoints in cUTI Trial ̶. ̶ Company Continues to Prepare for Commercialization of Eravacycline as a Treatment for cIAI in the U.S. and Europe, Assuming Regulatory ...


Tetraphase Pharmaceuticals Inc (TTPH) Forecasted to Post FY2022 Earnings of $0 ...
Week Herald - Nov 8, 2017
HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th.

Tetraphase Pharmaceuticals Inc (TTPH) Receives $17.00 Average Target Price ...
Week Herald - Jan 9, 2018
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the stock, Marketbeat.

Here's Why Tetraphase Pharmaceuticals Crashed 60.4% Today
Motley Fool - Feb 14, 2018
New antibiotics that can be used interchangeably with existing antibiotics to reduce the emergence of resistant bacteria is incredibly important and unfortunately, the cUTI data suggests that there will continue to be an unmet need for new options with ...
Tetraphase Pharma Shares Plunge After Antibiotic Fails Late-Stage Trial - Benzinga
Tetraphase's antibiotic fails late-stage study, shares plummet - Reuters

Tetraphase Pharmaceuticals Inc. (TTPH) Moves Lower on Volume Spike for February 16
Equities.com - Feb 16, 2018
Tetraphase Pharmaceuticals Inc. (TTPH) traded on unusually high volume on Feb. 16, as the stock lost 3.64% to close at $2.12.
Tetraphase Pharmaceuticals Inc (TTPH) Forecasted to Post FY2017 Earnings of ... - StockNewsTimes
Analysts See $-0.64 EPS for Tetraphase Pharmaceuticals, Inc. (TTPH) - BZ Weekly

Enter a stock symbol to view the stock details.